SITE011-0038

SITE011 (ITA) › SITE011-0038

SITE011-0038

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2025-10-10

enrolled

AEs

7

Serious

0

Dropout signal

–

Adverse events

7

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-02-18 (study day 303); relationship: not assessed

moderate assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-12-31 (study day 254); relationship: not assessed

moderate assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-13 (study day 236); relationship: not assessed

mild assessed

Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-06-17 (study day 57); relationship: NOT RELATED

severe assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-27 (study day 36); relationship: NOT RELATED

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-05-21 (study day 30); relationship: not assessed

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-05-16 (study day 25); relationship: NOT RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.